Western Blotting (WB), ELISA, Immunocytochemistry (ICC)
Specificity
CUEDC2 antibody will not cross-react with CUEDC1.
Purification
CUEDC2 Antibody is affinity chromatography purified via peptide column.
Immunogen
CUEDC2 antibody was raised against a 19 amino acid synthetic peptide from near the carboxy terminus of human CUEDC2. The immunogen is located within the last 50 amino acids of CUEDC2.
CUEDC2
Reactivity: Human
WB, IHC (p)
Host: Rabbit
Polyclonal
unconjugated
Application Notes
CUEDC2 antibody can be used for detection of CUEDC2 by Western blot at 1 - 2 μ,g/mL. Antibody can also be used for immunocytochemistry starting at 5 μ,g/mL.
Antibody validated: Western Blot in human samples and Immunocytochemistry in human samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
CUEDC2 Antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
CUEDC2 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CUEDC2 Antibody: The CUE (coupling of ubiquitin conjugation to endoplasmic reticulum degradation) domain is an evolutionarily conserved, ~40 amino acid monoubiquitin-binding domain that mediates intramolecular monoubiquitylation. CUE domains are present in eukaryotic proteins that are involved in ubiquitination and protein trafficking pathways and may be required for ubiquitination of the proteins in which they are found. CUEDC2 (CUE domain-containing protein 2) was found through a yeast two-hybrid screening as a protein that interacts with the progesterone receptor (PR) and promotes progesterone-induced PR degradation by the ubiquitin-proteasome pathway. CUEDC2 also decreases the sumoylation of PR. CUEDC2 has also been found to interact with IKK-alpha and IKK-beta and decrease the activation of NF-κ,B by decreasing the activation of IKK.